Millicent Amankwah
Medical Oncology · Des Moines, IANPI 1881071223
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations.
Across 157 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$442
- AstraZeneca$362
- GSK$327
- Novartis$228
- Johnson & Johnson$223
- AbbVie$220
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,12494%
- Education$2006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 18 | $442 |
| AstraZeneca(2 entities) | 15 | $362 |
| GSK | 11 | $327 |
| Novartis | 13 | $228 |
| Johnson & Johnson | 13 | $223 |
| AbbVie | 10 | $220 |
| Genentech USA, Inc. | 4 | $194 |
| Pfizer | 9 | $162 |
| Stemline Therapeutics Inc. | 6 | $106 |
| Bristol Myers Squibb | 5 | $80 |
| Astellas Pharma US Inc | 5 | $79 |
| E.r. Squibb & Sons, L.L.C. | 5 | $78 |
| Merck | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 4 | $69 |
| Eisai Inc. | 3 | $51 |
| Dendreon Pharmaceuticals LLC | 2 | $50 |
| Bayer | 3 | $48 |
| Seagen Inc. | 3 | $45 |
| Sanofi | 2 | $41 |
| Lilly USA, LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Sobi, Inc | 2 | $32 |
| Exelixis Inc. | 1 | $25 |
| Gilead | 1 | $24 |
| Recordati_rare_diseases_inc. | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Incyte Corporation | 1 | $22 |
| Geron Corporation | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Beone Medicines USA, Inc. | 1 | $19 |
| BTG International Inc. | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Emmaus Medical, Inc. | 1 | $16 |
| Genmab U.S., Inc. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,324 in reported general payments places this provider in the 70th percentile of 47 medical oncology providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 15 | $184,130 |
| NubeqaDarolutamide | 11 | $154,433 |
| Abiraterone Acetate | 14 | $39,933 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $901 |
| Morphine Sulfate ErMorphine Sulfate | 32 | $872 |
| Oxycodone Hcl | 37 | $582 |
| Ondansetron OdtOndansetron | 31 | $383 |
| Olanzapine | 31 | $208 |
| Letrozole | 14 | $205 |
| Dexamethasone | 22 | $195 |
| Amlodipine Besylate | 18 | $129 |
| Prochlorperazine Maleate | 11 | $103 |
| LoperamideLoperamide Hcl | 15 | $99 |
| Prednisone | 22 | $80 |
| Tamsulosin Hcl | 14 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $228 | $184,13015 claims |
| BayerNubeqa | $48 | $154,43311 claims |
| Lilly USA, LLCOlanzapine | $38 | $20831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 47 medical oncology providers in Iowa.
Other medical oncology in Des Moines
- Mathew WehbeDes Moines$120K
- Giselle MeryDes Moines$12K
- Emily BrugioniDes Moines$6K
- Steven HeddingerDes Moines$3K
- Christian SchultheisDes Moines$432
- Matthew HillDes Moines$378
- Magdy ElsawyDes Moines$353
- Robert BehrensDes Moines$345
- Bradley HiattDes Moines$148
- Sydney BrehanyDes Moines$141
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.